. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: J Pharm Sci. 2015 Jul 6;104(10):3426–3439. doi: 10.1002/jps.24551

Table 4.

Combination Antiviral Activity of IQP-0528 and SAMT-10 Tested Against HIV-1.

Assay	Synergy/Antagonism at the 95% Confidence Interval (µM²%)		Interpretation
Assay	Replicate 1	Replicate 2	Interpretation
CEM-SS/HIV-1_IIIB CPE	162.62/−17.14	372.47/−2.36	Synergistic
PBMC/HIV-1_ZA/97/009 (Clade C R5)	0.22/−44.6	4.41/−25.51	Additive

Activity of the combination of IQP-0528 and SAMT-10 was evaluated against HIV-1 in CEM-SS cells and human PBMCs. These assays included two replicate antiviral combination assays. Within each replicate each compound concentration was evaluated in triplicate.